These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21063824)

  • 1. [10 years of treatment with TNF inhibitors--are we on the safe side?].
    Zink A; Schneider M
    Z Rheumatol; 2010 Nov; 69(9):772-3. PubMed ID: 21063824
    [No Abstract]   [Full Text] [Related]  

  • 2. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
    [No Abstract]   [Full Text] [Related]  

  • 3. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
    Mariette X
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
    [No Abstract]   [Full Text] [Related]  

  • 4. [Evidence based medicine in rheumatology].
    Gause A; Raspe HH
    Z Rheumatol; 2002 Oct; 61(5):516-8. PubMed ID: 12399877
    [No Abstract]   [Full Text] [Related]  

  • 5. Comment on prescribing tumor necrosis factor inhibitors.
    Hanauer LB
    Arthritis Rheum; 2002 Jun; 47(3):347-8. PubMed ID: 12115169
    [No Abstract]   [Full Text] [Related]  

  • 6. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
    [No Abstract]   [Full Text] [Related]  

  • 7. [TNF-alpha antagonists in therapy of rheumatoid arthritis].
    Gross WL; Gause A
    Z Rheumatol; 2003 Jun; 62(3):217. PubMed ID: 12931691
    [No Abstract]   [Full Text] [Related]  

  • 8. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
    Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
    J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Non-TNF biologicals in therapy].
    Wollenhaupt J; Burmester GR
    Z Rheumatol; 2010 Sep; 69(7):579-80. PubMed ID: 20703491
    [No Abstract]   [Full Text] [Related]  

  • 10. [Biological treatment of rheumatic diseases].
    Procházková L; Böhmová J; Soucek M
    Vnitr Lek; 2006 Jun; 52(6):632-9. PubMed ID: 16871769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biological treatment of rhematoid diseases].
    Pavelka K
    Vnitr Lek; 2006 Jun; 52(6):561-2. PubMed ID: 16871758
    [No Abstract]   [Full Text] [Related]  

  • 12. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade.
    Yelin E; Katz P
    Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010
    [No Abstract]   [Full Text] [Related]  

  • 13. Three years experience with the prescription of anti-TNF-alpha inhibitors at Dr Soliman Fakeeh Hospital in Jeddah, Saudi Arabia.
    Eleishi HH; Toma NF; Chaki MC; Nada HR
    Int J Rheum Dis; 2009 Apr; 12(1):14-9. PubMed ID: 20374311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update in rheumatology: evidence published in 2011.
    Forbess LJ; Bass AR
    Ann Intern Med; 2012 Jul; 157(2):114-9. PubMed ID: 22801673
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of biologics in rheumatology: improving the evidence base.
    Silman AJ; Ades AE
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv1-2. PubMed ID: 21859699
    [No Abstract]   [Full Text] [Related]  

  • 16. Is there a rationale for switching from one anti-tumor necrosis factor agent to another?
    Haraoui B
    J Rheumatol; 2004 Jun; 31(6):1021-2. PubMed ID: 15170907
    [No Abstract]   [Full Text] [Related]  

  • 17. Rheumatoid vasculitis treated with infliximab.
    van der Bijl AE; Allaart CF; Van Vugt J; Van Duinen S; Breedveld FC
    J Rheumatol; 2005 Aug; 32(8):1607-9. PubMed ID: 16078342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should tuberculin skin test be positive to give latent tuberculosis treatment before tumor necrosis factor-alpha inhibitors in selected patients in developing countries?
    Abud-Mendoza C; Martínez-Martínez MU; DE Jesús Macías-Mendoza J; Magaña-Aquino M
    J Rheumatol; 2010 Mar; 37(3):672-3; author reply 673. PubMed ID: 20197567
    [No Abstract]   [Full Text] [Related]  

  • 19. mAbs in nonlupus autoimmune rheumatic disease.
    Whelan BR; Isenberg DA
    Curr Opin Hematol; 2009 Jul; 16(4):280-4. PubMed ID: 19444098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pregnancy in rheumatic patients treated with biologic drugs].
    Sentić M; Baresić M; Anić B; Bosnić D; Cerovec M; Mayer M; Smiljanić L; Cikes N
    Lijec Vjesn; 2010; 132(9-10):317-8. PubMed ID: 21261033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.